Synribo (Omacetaxine Mepesuccinate) Patent Expiration, LOE Window & CMS Spending

Synribo (Omacetaxine Mepesuccinate) by Teva Pharmaceuticals: FDA Orange Book LOE 2026-10-26, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN203585 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-10-26
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.